Denmark suspended the use of AstraZeneca's vaccine for two weeks after reports of several cases of blood clots in vaccinees. One of the cases ended in death.

At the same time, the authorities of the country emphasized that a direct link between the formation of blood clots and vaccination has not yet been established. The European Medicines Agency said it would investigate, but stressed that the benefits of the vaccine outweigh the risks anyway.

Following Denmark, Norway and Iceland made similar decisions to suspend vaccination with the drug from AstraZeneca. The authorities of these countries emphasized that there were no cases of side effects recorded there, and the suspension was associated with information from Denmark.

AstraZeneca on March 11 Italy also suspended . This happened after the death of a 43-year-old man: he died of cardiac arrest the day after vaccination - the authorities intend to find out if the two events were connected.
On March 7, the use of AstraZeneca vaccines from one particular batch was discontinued in Austria after one of the vaccinated women died of bleeding disorders and the second was diagnosed with pulmonary embolism. In total, vaccines from this batch were sent to 17 EU countries, after Austria, Luxembourg, Estonia, Latvia and Lithuania announced their decision not to use drugs from this shipment. Estonia also recommended that patients with a high risk of thrombosis should not be vaccinated with AstraZeneca at all.
About five million Europeans have now been vaccinated with AstraZeneca's drug. Thrombus formation was recorded in 30 cases.

Denmark, Norway and Iceland have suspended use of the AstraZeneca vaccine due to cases of blood clots in those vaccinated